Manas Mishra

Merck's COVID-19 pill significantly less effective in new analysis

Nov 26 2021

(Reuters) -Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.

Flu vaccine demand takes off in India as pandemic raises awareness

Nov 23 2021

A pandemic-spurred demand for flu vaccines in India has surged since a devastating second wave of COVID-19 brought the nation's healthcare system to its knees earlier this year.

U.S. expands COVID-19 booster eligibility to all adults

Nov 21 2021

(This November 19 story was corrected to say 60% of Americans are fully vaccinated in last paragraph) | Video

COVID-19 'boosters-for-all' discussion moves to CDC

Nov 19 2021

Nov 19 More U.S. adults could be eligible for a booster dose of the COVID-19 vaccine if a panel of experts meets as planned on Friday and recommends that a third round of the shots would be beneficial for a broad population.

U.S. to buy 10 million courses of Pfizer's COVID-19 pill for $5.3 billion

Nov 18 2021

Pfizer Inc said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.

U.S. drug deaths surpass 100,000 for first time, spurred by pandemic

Nov 17 2021

More Americans than ever before died from drug overdoses over a 12-month period, according to federal data released on Wednesday, as the coronavirus pandemic disrupted medical care and increased mental health woes, and as more lethal drugs flooded the streets.

Biogen's Alzheimer's drug gets negative European panel vote

Nov 17 2021

(Reuters) -A European Medicines Agency panel voted against approval of Biogen Inc's Alzheimer's drug Aduhelm, in another blow to prospects for a treatment already grappling with a slow rollout in the United States. | Video

J&J to spin off consumer products and focus on pharmaceuticals

Nov 12 2021

Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history.

World News